Skip to main content
. 2017 Oct 26;35(36):4019–4026. doi: 10.1200/JCO.2017.73.8195

Fig 1.

Fig 1.

Overall survival (OS) based on 24-month event-free survival (EFS24) in initial and replication cohorts. (A) Subsequent OS of patients who did not achieve EFS24 (progression within 24 months after diagnosis) in the Molecular Epidemiology Resource (MER) and Sweden (SWE). (B) Subsequent OS of patients who achieved EFS24 in the MER and SWE cohorts. (C) Subsequent OS of patients who did not achieve EFS24 in the British Columbia Cancer Agency (BCCA) replication cohort. (D) Subsequent OS of patients who achieved EFS24 in the BCCA cohort. PTCL, peripheral T-cell lymphoma.